143 related articles for article (PubMed ID: 24789302)
1. Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.
Bachstetter AD; Watterson DM; Van Eldik LJ
J Neuroimmune Pharmacol; 2014 Sep; 9(4):454-60. PubMed ID: 24789302
[TBL] [Abstract][Full Text] [Related]
2. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).
Bachstetter AD; Xing B; de Almeida L; Dimayuga ER; Watterson DM; Van Eldik LJ
J Neuroinflammation; 2011 Jul; 8():79. PubMed ID: 21733175
[TBL] [Abstract][Full Text] [Related]
3. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
[TBL] [Abstract][Full Text] [Related]
4. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
[TBL] [Abstract][Full Text] [Related]
5. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo.
Tate CM; Blosser W; Wyss L; Evans G; Xue Q; Pan Y; Stancato L
J Biol Chem; 2013 Mar; 288(9):6743-53. PubMed ID: 23335506
[TBL] [Abstract][Full Text] [Related]
6. The p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanism.
Bachstetter AD; Xing B; Van Eldik LJ
J Neuroinflammation; 2014 Oct; 11():175. PubMed ID: 25297465
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages.
Smith SJ; Fenwick PS; Nicholson AG; Kirschenbaum F; Finney-Hayward TK; Higgins LS; Giembycz MA; Barnes PJ; Donnelly LE
Br J Pharmacol; 2006 Oct; 149(4):393-404. PubMed ID: 16953188
[TBL] [Abstract][Full Text] [Related]
8. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.
Watterson DM; Grum-Tokars VL; Roy SM; Schavocky JP; Bradaric BD; Bachstetter AD; Xing B; Dimayuga E; Saeed F; Zhang H; Staniszewski A; Pelletier JC; Minasov G; Anderson WF; Arancio O; Van Eldik LJ
PLoS One; 2013; 8(6):e66226. PubMed ID: 23840427
[TBL] [Abstract][Full Text] [Related]
9. Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase.
Guo X; Gerl RE; Schrader JW
J Biol Chem; 2003 Jun; 278(25):22237-42. PubMed ID: 12637577
[TBL] [Abstract][Full Text] [Related]
10. Deficiency in p38β MAPK fails to inhibit cytokine production or protect neurons against inflammatory insult in in vitro and in vivo mouse models.
Xing B; Bachstetter AD; Van Eldik LJ
PLoS One; 2013; 8(2):e56852. PubMed ID: 23457629
[TBL] [Abstract][Full Text] [Related]
11. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease.
Rutigliano G; Stazi M; Arancio O; Watterson DM; Origlia N
Neurobiol Aging; 2018 Oct; 70():86-91. PubMed ID: 30007168
[TBL] [Abstract][Full Text] [Related]
12. Selective requirement of p38alpha MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses.
Berenson LS; Yang J; Sleckman BP; Murphy TL; Murphy KM
J Immunol; 2006 Apr; 176(8):4616-21. PubMed ID: 16585552
[TBL] [Abstract][Full Text] [Related]
13. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2.
Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
Bioorg Med Chem Lett; 2012 Sep; 22(18):5979-83. PubMed ID: 22901390
[TBL] [Abstract][Full Text] [Related]
15. Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.
Zhou Z; Bachstetter AD; Späni CB; Roy SM; Watterson DM; Van Eldik LJ
J Neuroinflammation; 2017 Apr; 14(1):75. PubMed ID: 28381303
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease.
Docena G; Rovedatti L; Kruidenier L; Fanning A; Leakey NA; Knowles CH; Lee K; Shanahan F; Nally K; McLean PG; Di Sabatino A; MacDonald TT
Clin Exp Immunol; 2010 Oct; 162(1):108-15. PubMed ID: 20731675
[TBL] [Abstract][Full Text] [Related]
17. Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.
Alam JJ; Krakovsky M; Germann U; Levy A
PLoS One; 2020; 15(12):e0233073. PubMed ID: 33275615
[TBL] [Abstract][Full Text] [Related]
18. Identification of triazolopyridazinones as potent p38α inhibitors.
Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
